Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD


Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Related Videos
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
Marion Munk, MD, PhD, presenting slides
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
Antonio Filipe Macedo, OD, MSc, PhD, speaks about the 2024 ARVO meeting
Kasperi Kankare at the iCare booth at ESCRS
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, speaking at ASRS 2023.
© 2024 MJH Life Sciences

All rights reserved.